ReviewDrugs2008
Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections.
Review in Drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 77 citations in OpenAlex.
- NVC-422 topical gel for the treatment of impetigo.International journal of clinical and experimental pathology · 2011Trial
- Acute and 28-Day Toxicity Evaluation of New Pleuromutilin Derivative 4g.Journal of applied toxicology : JAT · 2026Article
- Methicillin-resistantiScience · 2026Review
- Emergence and spread of a mupirocin-resistant variant of the European epidemic fusidic acid-resistant impetigo clone ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium.The Journal of antimicrobial chemotherapy · 2023Article
- Design, Synthesis and Biological Evaluation of Novel Pleuromutilin Derivatives Containing 6-Chloro-1-R-1Molecules (Basel, Switzerland) · 2023Article
- Genome Assembly and Genetic Traits of the Pleuromutilin-ProducerJournal of fungi (Basel, Switzerland) · 2022Article
- Ten decadal advances in fungal biology leading towards human well-being.Fungal diversity · 2022Review
- Mycotic and Bacterial Infections.Clinics in colon and rectal surgery · 2019Review
- Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis.Nature chemistry · 2019Article
- Antibiotic Resistance and the MRSA Problem.Microbiology spectrum · 2019Review
- An Open Label, Multi-Center, Non-Interventional Post-Marketing Surveillance to Monitor the Safety and Efficacy of ALTARGO® (Retapamulin) Administered in Korean Patients According to the Prescribing Information.Annals of dermatology · 2018Article
- Clinical and bacteriological efficacy of twice daily topical retapamulin ointment 1% in the management of impetigo and other uncomplicated superficial skin infections.International journal of women's dermatology · 2015Article
- The cellulitis season is open.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2014Article
- In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice.Antimicrobial agents and chemotherapy · 2013Article
- Noninvasive in vivo imaging to evaluate immune responses and antimicrobial therapy against Staphylococcus aureus and USA300 MRSA skin infections.The Journal of investigative dermatology · 2011Article
- Establishing molecular tools for genetic manipulation of the pleuromutilin-producing fungus Clitopilus passeckerianus.Applied and environmental microbiology · 2009Article
- Impetigo - review.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Topical retapamulin (Altabax, Altargo) is the first pleuromutilin antibacterial approved for the treatment of uncomplicated superficial skin infections caused by Staphylococcus aureus (excluding meticillin-resistant S. aureus [MRSA]) and Streptococcus pyogenes in patients aged > or = 9 months. In the EU, retapamulin is indicated for use in patients with impetigo or with infected small lacerations, abrasions or sutured wounds (without abscesses); in the US, it is indicated for use in patients with impetigo. Retapamulin has a novel site of action on bacterial ribosomes. In clinical trials in patients with impetigo, topical retapamulin 1% ointment twice daily for 5 days (the approved regimen) was superior to placebo; treatment with retapamulin was noninferior to that with topical fusidic acid. In patients with secondarily infected traumatic lesions, treatment with retapamulin was noninferior to that with oral cefalexin, although the efficacy of retapamulin was reduced in patients with MRSA infections or superficial abscesses. Retapamulin was well tolerated in both paediatric and adult patients, and the majority of adverse events were of mild to moderate severity. Thus, the introduction of topical retapamulin 1% ointment extends the treatment options available in the management of impetigo and uncomplicated secondarily infected traumatic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.